title: Prevention and treatment of postpartum hypertension.
abstract: BACKGROUND
  Postpartum blood pressure (BP) is highest three to six days after birth when most women have been discharged home. A significant rise in BP may be dangerous (e.g., can lead to stroke), but there is little information about how to prevent or treat postpartum hypertension.
  
  
  OBJECTIVE
  To assess the relative benefits and risks of interventions to: (1) prevent postpartum hypertension, by assessing whether 'routine' postpartum medical therapy is better than placebo/no treatment; and (2) treat postpartum hypertension, by assessing whether (i) one antihypertensive therapy is better than placebo/no therapy for mild-moderate postpartum hypertension; and (ii) one antihypertensive agent offers advantages over another for mild-moderate or severe postpartum hypertension.
  
  
  METHODS
  We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 January 2013), bibliographies of retrieved papers, and personal files.
  
  
  METHODS
  For women with antenatal hypertension, trials comparing a medical intervention with placebo/no therapy. For women with postpartum hypertension, trials comparing one antihypertensive with either another or placebo/no therapy.
  
  
  METHODS
  We extracted the data independently and were not blinded to trial characteristics or outcomes. We contacted authors for missing data when possible.
  
  
  RESULTS
  Nine trials are included.
  
  
  CONCLUSIONS
  Four trials (358 women) compared furosemide, nifedipine capsules, or L-arginine with placebo/no therapy. For women with antenatal pre-eclampsia, postnatal furosemide is associated with a strong trend towards reduced use of antihypertensive therapy in hospital.
  
  
  METHODS
  For treatment of mild-moderate postpartum hypertension, three trials (189 women) compared timolol, oral hydralazine, or oral nifedipine with methyldopa. Use of additional antihypertensive therapy did not differ between groups (risk ratio (RR) 0.92, 95% confidence interval (CI) 0.20 to 4.20; three trials), but the trials were not consistent in their effects. The drugs were well tolerated.For treatment of severe postpartum hypertension, two trials (120 women) compared intravenous hydralazine with either sublingual nifedipine or intravenous labetalol. There were no maternal deaths or hypotension. Use of additional antihypertensive therapy did not differ between groups (RR 0.58, 95% CI 0.04 to 9.07; two trials), but the trials were not consistent in their effects.
  
  
  CONCLUSIONS
  For women with pre-eclampsia, postnatal furosemide may decrease the need for postnatal antihypertensive therapy in hospital, but more data are needed on substantive outcomes before this practice can be recommended. There are no reliable data to guide management of women who are hypertensive postpartum. Any antihypertensive agent used should be based on a clinician's familiarity with the drug. Future studies should include data on postpartum analgesics, severe maternal hypertension, breastfeeding, hospital length of stay, and maternal satisfaction with care.
authors: Departments of Internal Medicine (UBC) and Specialized Women’s Health (BC Women’s Hospital), British Columbia Women’sHospital and Health Centre, Vancouver, Canada. lmagee@cw.bc.ca.
authors: Laura
authors: L
authors: Magee
authors: Peter
authors: P
authors: von Dadelszen
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000517:prevention & control*; D011225:Pre-Eclampsia / Q000188:drug therapy; D011247:Pregnancy; D011644:Puerperal Disorders / Q000188:drug therapy* / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000959:Antihypertensive Agents
references: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004351
references: 15674943
references: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Jul;27(7):644-6
references: 17717930
references: S Afr Med J. 1988 Sep 17;74(6):265-7
references: 3420465
references: Hypertens Pregnancy. 2002;21(2):161-74
references: 12175444
references: Aust N Z J Obstet Gynaecol. 2007 Aug;47(4):279-85
references: 17627681
references: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001449
references: 16855969
references: Am J Obstet Gynecol. 1990 Mar;162(3):788-92
references: 2316590
references: Anaesthesia. 1999 Mar;54(3):207-9
references: 10364853
references: Am J Obstet Gynecol. 1984 Jul 1;149(5):496-500
references: 6377898
references: Hypertens Pregnancy. 2002;21(3):225-34
references: 12517329
references: J Soc Gynecol Investig. 1994 Jul-Sep;1(3):210-4
references: 9419773
references: Obstet Gynecol. 1987 Sep;70(3 Pt 1):328-33
references: 3306494
references: Ginecol Obstet Mex. 1991 Jul;59:207-10
references: 1769603
references: Am J Obstet Gynecol. 1999 Oct;181(4):862-6
references: 10521743
references: Am J Obstet Gynecol. 1964 Mar 15;88:788-90
references: 14130342
references: Hypertens Pregnancy. 2007;26(2):163-71
references: 17469006
references: Br J Obstet Gynaecol. 1997 Oct;104(10):1180-3
references: 9332997
references: Curr Med Res Opin. 1985;9(8):578-85
references: 3896665
references: J Matern Fetal Med. 1996 Jul-Aug;5(4):201-5
references: 8796794
references: Am J Obstet Gynecol. 2000 Jul;183(1):S1-S22
references: 10920346
references: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002252
references: 17253478
references: Obstet Gynecol. 2005 Jan;105(1):29-33
references: 15625138
references: Obstet Gynecol. 1993 Apr;81(4):502-6
references: 8459956
references: Obstet Gynecol. 2006 Apr;107(4):886-95
references: 16582128
references: Br J Obstet Gynaecol. 1982 Dec;89(12):1031-4
references: 7171513
references: BMJ. 1994 Nov 26;309(6966):1395-400
references: 7819845
references: Res Commun Chem Pathol Pharmacol. 1993 Sep;81(3):271-91
references: 8235062
references: Am J Obstet Gynecol. 1994 Aug;171(2):506-12
references: 8059832
references: Am J Obstet Gynecol. 1999 Oct;181(4):858-61
references: 10521742
references: Clin Sci (Lond). 1986 Nov;71(5):589-94
references: 3769407
references: Obstet Gynecol. 1986 Jul;68(1):86-90
references: 3725262
references: Obstet Gynecol. 2006 Oct;108(4):833-8
references: 17012443
references: Am J Obstet Gynecol. 2004 Feb;190(2):577-8
references: 14981414
references: CMAJ. 1997 Nov 1;157(9):1245-54
references: 9361646
references: Am J Perinatol. 1989 Oct;6(4):437-41
references: 2789542
references: Am J Obstet Gynecol. 1985 Sep 15;153(2):130-4
references: 2931024
references: Am J Obstet Gynecol. 1961 May;81:884-9
references: 13716875
references: Lancet. 1987 Aug 8;2(8554):330
references: 2886783
references: Am J Obstet Gynecol. 1994 Dec;171(6):1642-51
references: 7802082
references: Clin Exp Obstet Gynecol. 2006;33(1):55-8
references: 16761542
references: Afr J Med Med Sci. 1993 Mar;22(1):11-6
references: 7839876
references: BJOG. 2002 Jul;109(7):733-6
references: 12135206
references: J Matern Fetal Med. 1997 Nov-Dec;6(6):329-33
references: 9438215
references: J Obstet Gynaecol. 1997 Jan;17(1):30-2
references: 15511760
references: Aust N Z J Obstet Gynaecol. 2000 May;40(2):133-8
references: 10925899
references: Am J Obstet Gynecol. 1989 May;160(5 Pt 1):1112-6
references: 2524972
references: Clin Exp Hypertens B. 1982;1(2-3):371-83
references: 7139977
references: Hypertens Pregnancy. 2002;21(1):85-95
references: 12044345
references: Obstet Gynecol. 2003 Feb;101(2):217-20
references: 12576241